Myasthenia Gravis Market Overview
Market Research Future (MRFR) proclaims that the global myasthenia gravis market Share Size was valued at USD 0.8 billion in 2022 and is projected to grow from USD 0.9 Billion in 2023 to USD 1.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.80% during the forecast period (2023 - 2030).The surging cases of neuromuscular disorders are estimated to favor the market growth globally. Myasthenia gravis Insights is referred to as a neuromuscular disorder which results in the skeletal muscles to weaken. The disease generally occurs due to the impairment of communication between the nerve cells and the muscles and causes difficulty in the relaxation and contraction of muscles. The antibodies present in the body destroy the receptor for acetylcholine at the neuromuscular joint which prevents the muscles from contracting and performing its normal function.
Myasthenia Gravis can occur both in females and males but usually affect the women under 40 years and the aging population from 50 to 70 years. With surging cases of neuromuscular disorders, a growing number of clinical facilities, and raising awareness regarding the treatment line, the global myasthenia gravis disease is considered to receive a boost. The increasing occurrences of autoimmune disorders, rising spending on healthcare, and a strong pipeline in the treatment are some of the factors contributing to the growth of the market. The surging cases of myasthenia gravis market can impact the quality of life, which further fosters its growth. With the growth in RD activities, the Myasthenia Gravis Market Trends is likely to experience a thrust. Moreover, the rising adoption of novel therapies coupled with the favorable reimbursement policies especially in the developed economies has promoted its growth worldwide.
On the contrary, the ignorance symptoms and signs coupled with the high cost of treatment are some of the top barriers vitiating the market growth across the globe. Moreover, the limited availability of FDA approved drugs is estimated to deter the market growth in the long run.
Myasthenia Gravis Market Segmentation
The global myasthenia gravis disease market Outlook has been segmented on the basis of treatment, diagnosis, and end-user.
By mode of diagnosis, the global myasthenia gravis disease market has been segmented into blood tests, imaging, edrophonium tests, electrodiagnostic, pulmonary function tests, and others.
By mode of treatment, the global myasthenia gravis disease market has been segmented into surgery, medication, plasmapheresis and intravenous immunoglobulin, autologous Hematopoietic Stem Cell Transplantation (HSCT), and others.
By mode of end-users, the global myasthenia gravis disease market has been segmented into clinics, hospitals, academic research institutes, and others.
Myasthenia Gravis Market Regional Analysis
Geographically, the myasthenia gravis disease market span across regions namely, Europe, America, Asia Pacific, and the Middle East and Africa.
Considering the global scenario, the American region is estimated to command the largest market share. The growth is ascribed to the surging number of drug manufacturers, increased government funding for the treatment, and growing awareness regarding the long-term effects of muscle dystrophy. Major companies in this region are launching FDA approved drugs which have augmented the commercial access to such drugs on a global scale.
The European region is considered to occupy the second spot and is likely to retain its pole position in the long run. The growth can be ascribed to the adoption of the latest therapies, high availability of advanced treatment facilities, and the presence of skilled medical professionals.
The Asia Pacific region is estimated to be the fastest growing region due to the presence of a large geriatric population base especially in economies like China and Japan. The surging awareness regarding the long-term effects of muscular dystrophies has further contributed to the market growth. Moreover, the rising awareness regarding neuromuscular disorders coupled with the vast improvement made in the healthcare sector in economies like China, India, Malaysia, and Indonesia has further influenced the market growth to a large extent.
global myasthenia gravis disease market Players comprises AbbVie Inc. (U.S.), F. Hoffmann Roche La Ltd. (Switzerland), Biogen Inc. (U.S.), Fresenius Kabi (Germany), Cipla (India), Sun Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Apotex Corporation (Canada), RPG Life Sciences (India), Teva Pharmaceutical Industries Ltd. (Israel), Bristol-Myers Squibb Company (U.S.), Valeant Pharmaceuticals International (U.S.), Novartis Pharmaceuticals Corporation (Switzerland), GlaxoSmithKline plc (UK), and others.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071